In this study, we found that knockdown of TLR4 not only inhibits STAT3 activation, but also induces STAT3 protein degradation, suggesting an alternative approach to blocking STAT3 signaling in melanoma: genetically or pharmacologically inhibiting TLR4. This evidence concerns the gene TLR4 and melanoma.